These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7575356)

  • 1. Antagonistic mutant proteins of interleukin-4.
    Duschl A; Müller T; Sebald W
    Behring Inst Mitt; 1995 Jun; (96):87-94. PubMed ID: 7575356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific antagonism of type I IL-4 receptor with a mutated form of murine IL-4.
    Schnare M; Blum H; Jüttner S; Röllinghoff M; Gessner A
    J Immunol; 1998 Oct; 161(7):3484-92. PubMed ID: 9759868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the signal transducer glycoprotein 130 by both IL-6 and IL-11 requires two distinct binding epitopes.
    Kurth I; Horsten U; Pflanz S; Dahmen H; Küster A; Grötzinger J; Heinrich PC; Müller-Newen G
    J Immunol; 1999 Feb; 162(3):1480-7. PubMed ID: 9973404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of the human IgE response.
    de Vries JE; Yssel H
    Eur Respir J Suppl; 1996 Aug; 22():58s-62s. PubMed ID: 8871045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional and receptor binding characterization of recombinant murine macrophage inflammatory protein 2: sequence analysis and mutagenesis identify receptor binding epitopes.
    Jerva LF; Sullivan G; Lolis E
    Protein Sci; 1997 Aug; 6(8):1643-52. PubMed ID: 9260277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solution structure of human IL-13 and implication for receptor binding.
    Moy FJ; Diblasio E; Wilhelm J; Powers R
    J Mol Biol; 2001 Jun; 310(1):219-30. PubMed ID: 11419948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An antagonistic IL-4 mutant prevents type I allergy in the mouse: inhibition of the IL-4/IL-13 receptor system completely abrogates humoral immune response to allergen and development of allergic symptoms in vivo.
    Grunewald SM; Werthmann A; Schnarr B; Klein CE; Bröcker EB; Mohrs M; Brombacher F; Sebald W; Duschl A
    J Immunol; 1998 Apr; 160(8):4004-9. PubMed ID: 9558109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspects of receptor binding and signalling of interleukin-4 investigated by site-directed mutagenesis and NMR spectroscopy.
    Müller T; Dieckmann T; Sebald W; Oschkinat H
    J Mol Biol; 1994 Apr; 237(4):423-36. PubMed ID: 8151703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-4 induces human B cell maturation and IgE synthesis in SCID-hu mice. Inhibition of ongoing IgE production by in vivo treatment with an IL-4/IL-13 receptor antagonist.
    Carballido JM; Schols D; Namikawa R; Zurawski S; Zurawski G; Roncarolo MG; de Vries JE
    J Immunol; 1995 Nov; 155(9):4162-70. PubMed ID: 7594571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonredundant roles for CD1d-restricted natural killer T cells and conventional CD4+ T cells in the induction of immunoglobulin E antibodies in response to interleukin 18 treatment of mice.
    Yoshimoto T; Min B; Sugimoto T; Hayashi N; Ishikawa Y; Sasaki Y; Hata H; Takeda K; Okumura K; Van Kaer L; Paul WE; Nakanishi K
    J Exp Med; 2003 Apr; 197(8):997-1005. PubMed ID: 12695491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A model of the complex between interleukin-4 and its receptors.
    Gustchina A; Zdanov A; Schalk-Hihi C; Wlodawer A
    Proteins; 1995 Feb; 21(2):140-8. PubMed ID: 7777489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solution structure of interleukin-13 and insights into receptor engagement.
    Eisenmesser EZ; Horita DA; Altieri AS; Byrd RA
    J Mol Biol; 2001 Jun; 310(1):231-41. PubMed ID: 11419949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine recognition by human interleukin 5 receptor.
    Ishino T; Robertson N; Chaiken I
    Vitam Horm; 2005; 71():321-44. PubMed ID: 16112273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epitope peptides from interleukin-6 receptor which inhibit the growth of human myeloma cells.
    Halimi H; Eisenstein M; Oh JW; Revel M; Chebath J
    Eur Cytokine Netw; 1995; 6(3):135-43. PubMed ID: 8589270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of a functional IL-13Ralpha1 by rat B cells.
    Pierrot C; Beniguel L; Bègue A; Khalife J
    Biochem Biophys Res Commun; 2001 Oct; 287(4):969-76. PubMed ID: 11573960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The human IL-11 receptor requires gp130 for signalling: demonstration by molecular cloning of the receptor.
    Nandurkar HH; Hilton DJ; Nathan P; Willson T; Nicola N; Begley CG
    Oncogene; 1996 Feb; 12(3):585-93. PubMed ID: 8637716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biology of natural and recombinant soluble interleukin-4 receptor.
    Enssle K; Enders B; Kurrle R; Lauffer L; Schorlemmer HU; Dickneite G; Kanzy EJ; Seiler FR
    Behring Inst Mitt; 1995 Jun; (96):103-17. PubMed ID: 7575346
    [No Abstract]   [Full Text] [Related]  

  • 18. An interleukin 4 (IL-4) mutant protein inhibits both IL-4 or IL-13-induced human immunoglobulin G4 (IgG4) and IgE synthesis and B cell proliferation: support for a common component shared by IL-4 and IL-13 receptors.
    Aversa G; Punnonen J; Cocks BG; de Waal Malefyt R; Vega F; Zurawski SM; Zurawski G; de Vries JE
    J Exp Med; 1993 Dec; 178(6):2213-8. PubMed ID: 7504061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monomeric and dimeric forms of soluble receptors can differ in their neutralization potential.
    Lauffer L; Kanzy EJ; Köhler R; Kurrle R; Enssle K; Seiler FR
    Behring Inst Mitt; 1995 Jun; (96):21-31. PubMed ID: 7575349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure, binding, and antagonists in the IL-4/IL-13 receptor system.
    Mueller TD; Zhang JL; Sebald W; Duschl A
    Biochim Biophys Acta; 2002 Nov; 1592(3):237-50. PubMed ID: 12421669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.